JP2018510622A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018510622A5 JP2018510622A5 JP2017542900A JP2017542900A JP2018510622A5 JP 2018510622 A5 JP2018510622 A5 JP 2018510622A5 JP 2017542900 A JP2017542900 A JP 2017542900A JP 2017542900 A JP2017542900 A JP 2017542900A JP 2018510622 A5 JP2018510622 A5 JP 2018510622A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- polypeptide
- mutant
- position corresponding
- variant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 229920001184 polypeptide Polymers 0.000 claims 14
- 102000004196 processed proteins & peptides Human genes 0.000 claims 14
- 108090000765 processed proteins & peptides Proteins 0.000 claims 14
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 235000001014 amino acid Nutrition 0.000 claims 4
- 229940024606 amino acid Drugs 0.000 claims 4
- 150000001413 amino acids Chemical class 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 239000004475 Arginine Substances 0.000 claims 3
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 claims 3
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 claims 3
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims 3
- 235000009582 asparagine Nutrition 0.000 claims 3
- 229960001230 asparagine Drugs 0.000 claims 3
- 238000003556 assay Methods 0.000 claims 3
- 230000005847 immunogenicity Effects 0.000 claims 3
- 102000005927 Cysteine Proteases Human genes 0.000 claims 2
- 108010005843 Cysteine Proteases Proteins 0.000 claims 2
- 241000588724 Escherichia coli Species 0.000 claims 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims 2
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 2
- 239000004472 Lysine Substances 0.000 claims 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims 2
- 239000004473 Threonine Substances 0.000 claims 2
- 235000003704 aspartic acid Nutrition 0.000 claims 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims 2
- 238000012217 deletion Methods 0.000 claims 2
- 230000037430 deletion Effects 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 claims 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 claims 2
- 230000002163 immunogen Effects 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 claims 1
- 239000004471 Glycine Substances 0.000 claims 1
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 claims 1
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 claims 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 claims 1
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 claims 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 claims 1
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 235000004279 alanine Nutrition 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 235000018417 cysteine Nutrition 0.000 claims 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 235000013922 glutamic acid Nutrition 0.000 claims 1
- 239000004220 glutamic acid Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 230000001404 mediated effect Effects 0.000 claims 1
- 229930182817 methionine Natural products 0.000 claims 1
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 150000007523 nucleic acids Chemical group 0.000 claims 1
- 230000001717 pathogenic effect Effects 0.000 claims 1
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB201502305A GB201502305D0 (en) | 2015-02-12 | 2015-02-12 | Protein |
| GB1502305.4 | 2015-02-12 | ||
| PCT/EP2016/053054 WO2016128559A1 (en) | 2015-02-12 | 2016-02-12 | Cysteine protease |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018510622A JP2018510622A (ja) | 2018-04-19 |
| JP2018510622A5 true JP2018510622A5 (enExample) | 2019-03-28 |
| JP6879921B2 JP6879921B2 (ja) | 2021-06-02 |
Family
ID=52781455
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017542900A Active JP6879921B2 (ja) | 2015-02-12 | 2016-02-12 | システインプロテアーゼ |
Country Status (28)
| Country | Link |
|---|---|
| US (3) | US10758597B2 (enExample) |
| EP (2) | EP4265719A1 (enExample) |
| JP (1) | JP6879921B2 (enExample) |
| KR (1) | KR102524594B1 (enExample) |
| CN (2) | CN113564150B (enExample) |
| AU (1) | AU2016217801B2 (enExample) |
| BR (1) | BR112017017286A2 (enExample) |
| CA (1) | CA2976016C (enExample) |
| CL (1) | CL2017002066A1 (enExample) |
| CO (1) | CO2017009060A2 (enExample) |
| DK (1) | DK3256579T5 (enExample) |
| EA (1) | EA035896B1 (enExample) |
| ES (1) | ES2962794T3 (enExample) |
| FI (1) | FI3256579T3 (enExample) |
| GB (1) | GB201502305D0 (enExample) |
| HR (1) | HRP20231496T1 (enExample) |
| HU (1) | HUE064122T2 (enExample) |
| IL (1) | IL253939B (enExample) |
| LT (1) | LT3256579T (enExample) |
| MX (1) | MX391632B (enExample) |
| MY (1) | MY187486A (enExample) |
| PL (1) | PL3256579T3 (enExample) |
| PT (1) | PT3256579T (enExample) |
| RS (1) | RS64840B1 (enExample) |
| SG (1) | SG11201706349YA (enExample) |
| SI (1) | SI3256579T1 (enExample) |
| WO (1) | WO2016128559A1 (enExample) |
| ZA (1) | ZA201705114B (enExample) |
Families Citing this family (46)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201413240D0 (en) * | 2014-07-25 | 2014-09-10 | Hansa Medical Ab | Method |
| GB201502306D0 (en) | 2015-02-12 | 2015-04-01 | Hansa Medical Ab | Protein |
| GB201502305D0 (en) | 2015-02-12 | 2015-04-01 | Hansa Medical Ab | Protein |
| US20210228738A1 (en) * | 2017-07-17 | 2021-07-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins |
| CN108410798A (zh) * | 2018-03-27 | 2018-08-17 | 福建三造血技术有限公司 | 细胞分离用微珠洗脱液及配制方法 |
| MX2020010464A (es) | 2018-04-03 | 2021-01-29 | Vectores de virus que evitan anticuerpos. | |
| US12116384B2 (en) | 2018-04-03 | 2024-10-15 | Ginkgo Bioworks, Inc. | Virus vectors for targeting ophthalmic tissues |
| EP3774852A1 (en) | 2018-04-03 | 2021-02-17 | Stridebio, Inc. | Antibody-evading virus vectors |
| WO2020102740A2 (en) * | 2018-11-16 | 2020-05-22 | Spark Therapeutics, Inc. | Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins |
| WO2020159970A1 (en) * | 2019-01-28 | 2020-08-06 | Duke University | Compositions and methods for evading humoral immunity |
| AU2020241888A1 (en) | 2019-03-21 | 2021-09-30 | Ginkgo Bioworks, Inc. | Recombinant adeno-associated virus vectors |
| DE102019112558A1 (de) | 2019-05-14 | 2020-11-19 | Claas Selbstfahrende Erntemaschinen Gmbh | Verfahren zur Wartung und/oder Reparatur einer landwirtschaftlichen Arbeitsmaschine |
| US20220347298A1 (en) | 2019-10-04 | 2022-11-03 | Ultragenyx Pharmaceutical Inc. | Methods for improved therapeutic use of recombinant aav |
| JP2022551739A (ja) | 2019-10-17 | 2022-12-13 | ストライドバイオ，インコーポレイテッド | ニーマン・ピック病ｃ型の治療のためのアデノ随伴ウイルスベクター |
| AU2020396490C1 (en) | 2019-12-06 | 2023-04-27 | Regeneron Pharmaceuticals, Inc. | Anti-VEGF protein compositions and methods for producing the same |
| IL294558A (en) * | 2020-01-22 | 2022-09-01 | Spark Therapeutics Inc | Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins |
| GB202002072D0 (en) | 2020-02-14 | 2020-04-01 | Hansa Biopharma AB | immunoglobulin detection and associated therapies |
| CN115151648A (zh) | 2020-02-14 | 2022-10-04 | 阿尔特拉吉尼克斯制药公司 | 用于治疗cdkl5缺陷障碍的基因疗法 |
| GB202003129D0 (en) | 2020-03-04 | 2020-04-15 | Hansa Biopharma AB | Conditioning regimen for transplant of stem cells |
| CN115803009A (zh) | 2020-05-08 | 2023-03-14 | 瑞泽恩制药公司 | 用于治疗眼病和癌症的vegf阱和微阱及方法 |
| GB202007431D0 (en) * | 2020-05-19 | 2020-07-01 | Hansa Biopharma AB | Cysteine protease |
| GB202007434D0 (en) * | 2020-05-19 | 2020-07-01 | Hansa Biopharma AB | Methods |
| JP7795790B2 (ja) | 2020-06-05 | 2026-01-08 | 上海宝済薬業股▲ふん▼有限公司 | 酵素とウィルスとの薬物組成物及びその使用 |
| JP2023532219A (ja) * | 2020-06-18 | 2023-07-27 | 上海宝済薬業有限公司 | 免疫グロブリン分解酵素ＩｄｅＥの突然変異体 |
| BR112023003145A2 (pt) | 2020-08-19 | 2023-05-09 | Sarepta Therapeutics Inc | Vetores de vírus adenoassociado para tratamento da síndrome de rett |
| US20230374083A1 (en) * | 2020-09-21 | 2023-11-23 | Shanghai Bao Pharmaceuticals Co., Ltd. | Pharmaceutical combination and use thereof |
| US20230374542A1 (en) | 2020-10-07 | 2023-11-23 | Asklepios Biopharmaceutical, Inc. | Therapeutic adeno-associated virus delivery of fukutin related protein (fkrp) for treating dystroglycanopathy. disorders including limb girdle 21 (lgmd21) |
| AU2022256479A1 (en) | 2021-04-16 | 2023-11-30 | AskBio Inc. | Rational polyploid aav virions that cross the blood brain barrier and elicit reduced humoral response |
| EP4079848A1 (en) | 2021-04-22 | 2022-10-26 | Genovis Ab | Immunoglobulin cleaving enzyme |
| FR3125965B1 (fr) * | 2021-08-05 | 2024-06-21 | Mc Saf | Conjugués anticorps-médicament |
| US20250019721A1 (en) | 2021-08-11 | 2025-01-16 | Ultragenyx Pharmaceutical Inc. | Compositions and methods for treating a muscular dystrophy |
| US20250325640A1 (en) | 2021-11-15 | 2025-10-23 | Hansa Biopharma AB | Methods for enhancing adoptive cell transfer immunotherapies |
| KR20240123827A (ko) | 2021-12-16 | 2024-08-14 | 상하이 바오 파마슈티컬스 컴퍼니 리미티드 | 항면역글로불린 분해 효소에 의해 효소 절단된 Fc 변이체 |
| EP4275701A1 (en) | 2022-05-13 | 2023-11-15 | Hansa Biopharma AB | Conditioning regimen for cell transplant |
| EP4302770A1 (en) | 2022-07-08 | 2024-01-10 | Hansa Biopharma AB | Regimen for enzymatic desensitisation |
| WO2024057095A1 (en) | 2022-09-14 | 2024-03-21 | Genovis Ab | Mutant protease |
| EP4349365A1 (en) | 2022-10-07 | 2024-04-10 | Hansa Biopharma AB | Co-treatment for gene therapy |
| CN118853710A (zh) * | 2022-11-08 | 2024-10-29 | 上海泰昶生物技术有限公司 | 生产免疫球蛋白g降解酶的工程菌株和工艺 |
| CN115998690B (zh) * | 2022-11-10 | 2024-07-26 | 上海泰昶生物技术有限公司 | 包含免疫球蛋白g降解酶的冻干制剂及其制备工艺 |
| EP4619443A2 (en) | 2022-11-18 | 2025-09-24 | Seismic Therapeutic, Inc. | Fc fusion molecules and uses thereof |
| US12129499B2 (en) | 2023-01-06 | 2024-10-29 | Seismic Therapeutic, Inc. | Protease variants and uses thereof |
| CN121263202A (zh) * | 2023-03-29 | 2026-01-02 | 赛勒斯生物科技股份有限公司 | IdeS变体蛋白及其使用方法 |
| WO2025103235A1 (zh) * | 2023-11-13 | 2025-05-22 | 上海宝济药业股份有限公司 | 一种免疫球蛋白降解酶IdeE的突变体 |
| WO2025256977A1 (en) | 2024-06-13 | 2025-12-18 | Bayer Aktiengesellschaft | Novel igm and igg cleaving enzymes |
| WO2025256978A1 (en) | 2024-06-13 | 2025-12-18 | Bayer Aktiengesellschaft | Variants of igm and igg cleaving enzymes |
| CN118497176B (zh) * | 2024-07-16 | 2025-01-21 | 苏州康聚生物科技有限公司 | 一种免疫球蛋白降解酶 |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4366241A (en) | 1980-08-07 | 1982-12-28 | Syva Company | Concentrating zone method in heterogeneous immunoassays |
| WO1997015592A1 (en) * | 1995-10-23 | 1997-05-01 | Incyte Pharmaceuticals, Inc. | Novel human cysteine protease |
| CA2421278A1 (en) * | 1998-03-11 | 1999-09-16 | Genentech, Inc. | Novel polypeptides and nucleic acids encoding the same |
| AU2002216863B8 (en) | 2000-12-21 | 2008-03-20 | Id Biomedical Corporation | Streptococcus pyogenes antigens and corresponding DNA fragments |
| GB0130228D0 (en) | 2001-12-18 | 2002-02-06 | Hansa Medica Ab | Protein |
| GB0511769D0 (en) * | 2005-06-09 | 2005-07-20 | Hansa Medical Ab | Treatment |
| WO2006131347A2 (en) | 2005-06-09 | 2006-12-14 | Hansa Medical Ab | Use of the ides proteinase (from s. pyogenes) for treating autoimmune diseases and graft rejection |
| GB0624874D0 (en) * | 2006-12-13 | 2007-01-24 | Hansa Medical Ab | Treatment |
| EP2190984B1 (en) | 2007-09-14 | 2013-09-04 | Genovis Ab | Methods and kits for purification and detection of glycosylated IgG |
| CN102026658A (zh) * | 2007-12-13 | 2011-04-20 | 英特瓦克公司 | 改进的免疫组合物 |
| ES2388017T3 (es) | 2007-12-21 | 2012-10-05 | Roche Glycart Ag | Ensayo de estabilidad de anticuerpos |
| JP5461586B2 (ja) | 2009-02-09 | 2014-04-02 | ロシュ グリクアート アクチェンゲゼルシャフト | 免疫グロブリングリコシル化パターン分析 |
| CA2799136A1 (en) | 2010-05-26 | 2011-12-01 | Intervacc Ab | Vaccine against streptococcal infections based on recombinant proteins |
| GB201115841D0 (en) | 2011-09-13 | 2011-10-26 | Genovis Ab | Protein and method |
| GB201201314D0 (en) | 2012-01-26 | 2012-03-07 | Isis Innovation | Composition |
| GB201316744D0 (en) | 2013-09-20 | 2013-11-06 | Genovis Ab | Method |
| GB201413240D0 (en) | 2014-07-25 | 2014-09-10 | Hansa Medical Ab | Method |
| GB201502306D0 (en) | 2015-02-12 | 2015-04-01 | Hansa Medical Ab | Protein |
| GB201502305D0 (en) | 2015-02-12 | 2015-04-01 | Hansa Medical Ab | Protein |
| US20210228738A1 (en) * | 2017-07-17 | 2021-07-29 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Compositions and methods for increasing or enhancing transduction of gene therapy vectors and for removing or reducing immunoglobulins |
-
2015
- 2015-02-12 GB GB201502305A patent/GB201502305D0/en not_active Ceased
-
2016
- 2016-02-12 CA CA2976016A patent/CA2976016C/en active Active
- 2016-02-12 JP JP2017542900A patent/JP6879921B2/ja active Active
- 2016-02-12 PT PT167042233T patent/PT3256579T/pt unknown
- 2016-02-12 CN CN202110810280.2A patent/CN113564150B/zh active Active
- 2016-02-12 EP EP23180077.2A patent/EP4265719A1/en active Pending
- 2016-02-12 FI FIEP16704223.3T patent/FI3256579T3/fi active
- 2016-02-12 PL PL16704223.3T patent/PL3256579T3/pl unknown
- 2016-02-12 KR KR1020177025524A patent/KR102524594B1/ko active Active
- 2016-02-12 HR HRP20231496TT patent/HRP20231496T1/hr unknown
- 2016-02-12 SI SI201631755T patent/SI3256579T1/sl unknown
- 2016-02-12 EA EA201791775A patent/EA035896B1/ru not_active IP Right Cessation
- 2016-02-12 HU HUE16704223A patent/HUE064122T2/hu unknown
- 2016-02-12 RS RS20231088A patent/RS64840B1/sr unknown
- 2016-02-12 CN CN201680021602.2A patent/CN107532158A/zh active Pending
- 2016-02-12 ES ES16704223T patent/ES2962794T3/es active Active
- 2016-02-12 DK DK16704223.3T patent/DK3256579T5/da active
- 2016-02-12 US US15/550,318 patent/US10758597B2/en active Active
- 2016-02-12 MY MYPI2017001125A patent/MY187486A/en unknown
- 2016-02-12 AU AU2016217801A patent/AU2016217801B2/en active Active
- 2016-02-12 SG SG11201706349YA patent/SG11201706349YA/en unknown
- 2016-02-12 LT LTEPPCT/EP2016/053054T patent/LT3256579T/lt unknown
- 2016-02-12 WO PCT/EP2016/053054 patent/WO2016128559A1/en not_active Ceased
- 2016-02-12 MX MX2017010389A patent/MX391632B/es unknown
- 2016-02-12 BR BR112017017286-0A patent/BR112017017286A2/pt not_active Application Discontinuation
- 2016-02-12 EP EP16704223.3A patent/EP3256579B1/en active Active
-
2017
- 2017-07-27 ZA ZA2017/05114A patent/ZA201705114B/en unknown
- 2017-08-10 IL IL253939A patent/IL253939B/en active IP Right Grant
- 2017-08-11 CL CL2017002066A patent/CL2017002066A1/es unknown
- 2017-09-04 CO CONC2017/0009060A patent/CO2017009060A2/es unknown
-
2020
- 2020-02-17 US US16/792,747 patent/US11524057B2/en active Active
-
2022
- 2022-11-08 US US18/053,676 patent/US20230302100A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018510622A5 (enExample) | ||
| JP2018506286A5 (enExample) | ||
| HRP20231496T1 (hr) | Cistein proteaza | |
| JP6866974B2 (ja) | 新規なエンドリシンポリペプチド | |
| EP3821906A1 (en) | Vaccine against rsv comprising modified f polypeptide | |
| JP2015504052A5 (enExample) | ||
| JP2008536483A5 (enExample) | ||
| JP2019533722A5 (enExample) | ||
| JP2018515088A5 (enExample) | ||
| JP2013517783A5 (enExample) | ||
| MX2012008999A (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX2012008998A (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX2012009000A (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| MX340016B (es) | Composicion farmaceutica para el tratamiento y/o prevencion del cancer. | |
| JP2014510519A5 (enExample) | ||
| AU2010288559A8 (en) | New endolysin OBPgpLYS | |
| JP2010522540A5 (enExample) | ||
| JP2011528222A5 (enExample) | ||
| RU2017132689A (ru) | СЛИТАЯ С Fc α-ЦЕПЬ ВЫСОКОАФФИННОГО РЕЦЕПТОРА IgE | |
| JP2006506942A5 (enExample) | ||
| CN106232616A (zh) | 两亲性合成抗菌肽、其药物组合物及其用途 | |
| JP2020518249A5 (enExample) | ||
| NZ736652A (en) | Short synthetic peptide for treating diseases and/or conditions related to angiogenesis | |
| JP2019505567A5 (enExample) | ||
| JP2005502332A5 (enExample) |